Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3

Blood

Volumn 91, Issue 5, 1998, Pages 1700-1705

  Amarante Mendes, Gustavo P ^b   Kim, Caryn Naekyung ^b   Liu, Linda ^b   Huang, Yue ^b   Perkins, Charles L ^b   Green, Douglas R ^b   Bhalla, Kapil ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST TRANSFORMATION; CHANNEL GATING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENETIC TRANSFECTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL;

EID: 0032032270     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.5.1700     Document Type: Article

References (47)

1. Witte ON: Role of the BCR-ABL oncogene in human leukemia: Fifteenth Richard and Hilda Rosenthal Foundation award lecture. Cancer Res 53:485, 1993
2. Gale PR, Grosveld G, Canaani E, Goldman JM: Chronic myelogenous leukemia: Biology and therapy. Leukemia 7:653, 1993
3. Bedi A, Barber JP, Bedi GC, El-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ: BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood 86:1148, 1995
4. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179, 1994
5. Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 45:321, 1975
6. s induces differentiation and sensitizes CML-blast crisis K562 cells to Ara-C mediated differentiation and apoptosis. Cell Growth Differ 7:1617, 1996
7. L. Blood 87:3837, 1996
8. L inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 56:4743, 1996
9. L Overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Differ 7:1087, 1996
10. Liu X, Zou H, Slaughter C, Wang X: DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 89:175, 1997
11. L inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res 57:3115, 1997
12. Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 86:147, 1996
13. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T-I, Jones DP, Wang X: Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 275:1129, 1997
14. L antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57:62, 1997
15. L forms an ion channel in synthetic lipid membranes. Nature 385:353, 1997
16. Amarante-Mendes GP, Jascur T, Nishioka WK, Mustelin T, Green DR: Bcr-Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity. Cell Growth Differ 4:548, 1997
17. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G, Willingham M: Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 8:465, 1994
18. Xiang J, Chao DT, Korsmeyer SJ: BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases. Proc Natl Acad Sci USA 93:14559, 1996
19. Wang X, Zelenski NG, Yang J, Sakai J, Brown MS, Goldstein JL: Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis. EMBO J 15:1012, 1996
20. Ray S, Ponnathpur V, Huang Y, Tang C, Mahoney ME, Ibrado AM, Bullock G, Bhalla K: 1-β-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: Improved method for detection of internucleosomal DNA fragmentation. Cancer Chemother Pharmacol 34:365, 1994
21. Jarvis WD, Fornari FA Jr, Traylor RS, Martin HA, Kramer LB, Erukulla RK, Bittman R, Grant S: Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingolipid bases in human myeloid leukemia cells. J Biol Chem 271:8275, 1996
22. Armstrong RC, Aja T, Xiang J, Gaur S, Krebs JF, Hoang K, Bai X, Korsmeyer SJ, Karanewsky DS, Fritz LC, Tomaselli KJ: Fasinduced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 271: 16850, 1996
23. Fernandes RS, Gorman AM, McGahon A, Lawlor M, McCann S, Cotter TG: The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia. Leukemia 10:S17, 1996 (suppl 2)
24. Golstein P: Controlling cell death. Science 275:1081, 1997
25. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405, 1997
26. Reed JC: Double identity for proteins of the Bcl-2 family. Nature 387:773, 1997
27. Haldar S, Jena N, Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92:4507, 1995
28. Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DGI, Higgs PI, Neckers L, Fojo T: Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res 57:130, 1997
29. Ito T, Deng X, Carr B, May WS: Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 272:11671, 1997
30. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275:1132, 1997
31. Gajewski TF, Thompson CB: Apoptosis meets signal transduction: Elimination of a BAD influence. Cell 87:589, 1996
32. L. Cell 87:619, 1996
33. Okuda K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD: Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol 22:1111, 1994
34. Wang HG, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87:629, 1996
35. Sanchez-Garcia I, Grutz G: Tumorigenic activity of the BCL-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 92:5287, 1995
36. Huang Y, Ray S, Reed JC, Ibrado AM, Tang C, Nawabi A, Bhalla K: Estrogen increases intracellular p26Bcl-2 or p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 42:73, 1997
37. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR: Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem 270:22625, 1995
38. L. Oncogene (in press)
39. Fuchs EJ, Bedi A, Jones RJ, Hess AD: Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 55:463, 1995
40. Roger R, Issaad C, Pallardy M, Léglise M-C. Turhan AG, Bertoglio J, Bréard J: BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated cells. Blood 87:1113, 1996
41. Hannun YA: Functions of ceramide in coordinating cellular responses to stress. Science 274:1855, 1996
42. Nagata S: Apoptosis by death factor. Cell 88:355, 1997
43. Dubrez L, Savoy I, Hamman A, Solary E: Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways. EMBO J 15:5504, 1996
44. L can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc Natl Acad Sci USA 94:3759, 1997
45. L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ 6:363, 1995
46. Jarvis WD, Grant S, Kolesnick RN: Ceramide and the induction of apoptosis. Clin Cancer Res 2:1, 1996
47. Landowski TH, Gleason-Guzman MC, Dalton WS: Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 89:1854, 1997